171 related articles for article (PubMed ID: 36195214)
1. The correlation between pre-treatment symptoms, acute and late toxicity and patient-reported health-related quality of life in non-small cell lung cancer patients: Results of the REQUITE study.
van der Weijst L; Azria D; Berkovic P; Boisselier P; Briers E; Bultijnck R; Chang-Claude J; Choudhury A; Defraene G; Demontois S; Elliott RM; Ennis D; Faivre-Finn C; Franceschini M; Giandini T; Giraldo A; Gutiérrez-Enríquez S; Herskind C; Higginson DS; Kerns SL; Johnson K; Lambrecht M; Lang P; Ramos M; Rancati T; Rimner A; Rosenstein BS; De Ruysscher D; Salem A; Sangalli C; Seibold P; Sosa Fajardo P; Sperk E; Stobart H; Summersgill H; Surmont V; Symonds P; Taboada-Valladares B; Talbot CJ; Vega A; Veldeman L; Veldwijk MR; Ward T; Webb A; West CML; Lievens Y;
Radiother Oncol; 2022 Nov; 176():127-137. PubMed ID: 36195214
[TBL] [Abstract][Full Text] [Related]
2. Overview of health-related quality of life and toxicity of non-small cell lung cancer patients receiving curative-intent radiotherapy in a real-life setting (the REQUITE study).
Van der Weijst L; Aguado-Barrera ME; Azria D; Berkovic P; Boisselier P; Briers E; Bultijnck R; Calvo-Crespo P; Chang-Claude J; Choudhury A; Defraene G; Demontois S; Dunning AM; Elliott RM; Ennis D; Faivre-Finn C; Franceschini M; Gutiérrez-Enríquez S; Herskind C; Higginson DS; Kerns SL; Johnson K; Mollà M; Lambrecht M; Ramos M; Rancati T; Rimner A; Rosenstein BS; De Ruysscher D; Salem A; Sangalli C; Seibold P; Sosa-Fajardo P; Sperk E; Stobart H; Summersgill H; Surmont V; Symonds P; Taboada-Lorenzo B; Talbot CJ; Valdagni R; Vega A; Veldeman L; Veldwijk MR; Ward T; Webb A; West CML; ; Lievens Y
Lung Cancer; 2022 Apr; 166():228-241. PubMed ID: 35334417
[TBL] [Abstract][Full Text] [Related]
3. Patient-reported outcomes and functional exercise capacity in a real-life setting in non-small cell lung cancer patients undergoing stereotactic body radiotherapy: the Lung PLUS study.
van der Weijst L; Bultijnck R; Van Damme A; Huybrechts V; van Eijkeren M; Lievens Y
Front Oncol; 2023; 13():1220248. PubMed ID: 37692843
[TBL] [Abstract][Full Text] [Related]
4. Real Life Data on Patient-Reported Outcomes and Neuro-Cognitive Functioning of Lung Cancer Patients: The PRO-Long Study.
Van Der Weijst L; Surmont V; Schrauwen W; Lievens Y
Front Oncol; 2021; 11():685605. PubMed ID: 34222010
[TBL] [Abstract][Full Text] [Related]
5. Patient-reported outcomes after personalised dose-escalation for stage II-III non-small-cell lung cancer patients: Results from the randomised ARTFORCE PET-Boost trial.
Cooke SA; Belderbos JSA; Reymen B; Lambrecht M; Fredberg Persson G; Faivre-Finn C; Dieleman EMT; van Diessen JNA; Sonke JJ; de Ruysscher D
Radiother Oncol; 2024 Jul; 196():110312. PubMed ID: 38663582
[TBL] [Abstract][Full Text] [Related]
6. Health-related quality of life in long-term survivors of unresectable locally advanced non-small cell lung cancer.
Ran J; Wang J; Bi N; Jiang W; Zhou Z; Hui Z; Liang J; Feng Q; Wang L
Radiat Oncol; 2017 Dec; 12(1):195. PubMed ID: 29197373
[TBL] [Abstract][Full Text] [Related]
7. Patient-reported health-related quality of life from a randomized phase II trial comparing standard-dose with high-dose twice daily thoracic radiotherapy in limited stage small-cell lung cancer.
Killingberg KT; Halvorsen TO; Fløtten Ø; Brustugun OT; Langer SW; Nyman J; Hornslien K; Madebo T; Schytte T; Risum S; Tsakonas G; Engleson J; Grønberg BH
Lung Cancer; 2022 Apr; 166():49-57. PubMed ID: 35183991
[TBL] [Abstract][Full Text] [Related]
8. Hypofractionated palliative radiotherapy (17 Gy per two fractions) in advanced non-small-cell lung carcinoma is comparable to standard fractionation for symptom control and survival: a national phase III trial.
Sundstrøm S; Bremnes R; Aasebø U; Aamdal S; Hatlevoll R; Brunsvig P; Johannessen DC; Klepp O; Fayers PM; Kaasa S
J Clin Oncol; 2004 Mar; 22(5):801-10. PubMed ID: 14990635
[TBL] [Abstract][Full Text] [Related]
9. Effect of Brain Metastasis on Patient-Reported Outcomes in Advanced NSCLC Treated in Real-World Community Oncology Settings.
Walker MS; Wong W; Ravelo A; Miller PJE; Schwartzberg LS
Clin Lung Cancer; 2018 Mar; 19(2):139-147. PubMed ID: 29103883
[TBL] [Abstract][Full Text] [Related]
10. Quality of life after stereotactic radiotherapy for stage I non-small-cell lung cancer.
van der Voort van Zyp NC; Prévost JB; van der Holt B; Braat C; van Klaveren RJ; Pattynama PM; Levendag PC; Nuyttens JJ
Int J Radiat Oncol Biol Phys; 2010 May; 77(1):31-7. PubMed ID: 19864077
[TBL] [Abstract][Full Text] [Related]
11. Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1-Expressing NSCLC.
Barlesi F; Garon EB; Kim DW; Felip E; Han JY; Kim JH; Ahn MJ; Fidler MJ; Gubens MA; de Castro G; Surmont V; Li Q; Deitz AC; Lubiniecki GM; Herbst RS
J Thorac Oncol; 2019 May; 14(5):793-801. PubMed ID: 30711649
[TBL] [Abstract][Full Text] [Related]
12. The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life.
Bergman B; Aaronson NK; Ahmedzai S; Kaasa S; Sullivan M
Eur J Cancer; 1994; 30A(5):635-42. PubMed ID: 8080679
[TBL] [Abstract][Full Text] [Related]
13. Clinical decision-making and health-related quality of life during first-line and maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC): findings from a real-world setting.
Sztankay M; Giesinger JM; Zabernigg A; Krempler E; Pall G; Hilbe W; Burghuber O; Hochmair M; Rumpold G; Doering S; Holzner B
BMC Cancer; 2017 Aug; 17(1):565. PubMed ID: 28835219
[TBL] [Abstract][Full Text] [Related]
14. Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: results of a randomized phase IIb/III trial (LUX-Lung 1).
Hirsh V; Cadranel J; Cong XJ; Fairclough D; Finnern HW; Lorence RM; Miller VA; Palmer M; Yang JC
J Thorac Oncol; 2013 Feb; 8(2):229-37. PubMed ID: 23328549
[TBL] [Abstract][Full Text] [Related]
15. Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung.
Byhardt RW; Scott C; Sause WT; Emami B; Komaki R; Fisher B; Lee JS; Lawton C
Int J Radiat Oncol Biol Phys; 1998 Oct; 42(3):469-78. PubMed ID: 9806503
[TBL] [Abstract][Full Text] [Related]
16. A Randomized Phase 3 Trial of Palliative Radiation Therapy Versus Concurrent Chemotherapy and Palliative Radiation Therapy in Patients With Good Performance Status, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer With Symptoms due to Intrathoracic Disease Who are Not Suitable for Radical Chemo-radiation Therapy: Results of the Trans-Tasman Radiation Oncology Group 11.03 Trial.
Lehman M; Bernard A; See A; King M; Michael M
Pract Radiat Oncol; 2021; 11(4):252-263. PubMed ID: 33271352
[TBL] [Abstract][Full Text] [Related]
17. High-dose radiotherapy or concurrent chemo-radiation in lung cancer patients only induces a temporary, reversible decline in QoL.
Pijls-Johannesma M; Houben R; Boersma L; Grutters J; Seghers K; Lambin P; Wanders R; De Ruysscher D
Radiother Oncol; 2009 Jun; 91(3):443-8. PubMed ID: 19297049
[TBL] [Abstract][Full Text] [Related]
18. Association between physical activity and health-related quality of life: time to deterioration model analysis in lung adenocarcinoma.
Zhuang J; Liu Y; Xu X; Cai Y; Liu M; Chen Z; Yang S; Lin J; Hu Z; Kang M; Lin M; He F
J Cancer Surviv; 2023 Dec; 17(6):1769-1779. PubMed ID: 36192668
[TBL] [Abstract][Full Text] [Related]
19. The impact of gastrointestinal and genitourinary toxicity on health related quality of life among irradiated prostate cancer patients.
Schaake W; Wiegman EM; de Groot M; van der Laan HP; van der Schans CP; van den Bergh AC; Langendijk JA
Radiother Oncol; 2014 Feb; 110(2):284-90. PubMed ID: 24411226
[TBL] [Abstract][Full Text] [Related]
20. Health-Related Quality of Life With Carboplatin-Paclitaxel or nab-Paclitaxel With or Without Pembrolizumab in Patients With Metastatic Squamous Non-Small-Cell Lung Cancer.
Mazieres J; Kowalski D; Luft A; Vicente D; Tafreshi A; Gümüş M; Laktionov K; Hermes B; Cicin I; Rodríguez-Cid J; Wilson J; Kato T; Ramlau R; Novello S; Reddy S; Kopp HG; Piperdi B; Li X; Burke T; Paz-Ares L
J Clin Oncol; 2020 Jan; 38(3):271-280. PubMed ID: 31751163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
